| Stockholders' Equity | NOTE 12 – STOCKHOLDERS’
EQUITY The Company issued the following shares of
common stock during the Fiscal 2020:
Number of Fair Value Fair Value at Issuance
Common Shares of Shares (minimum and maximum
Shares issued to/for: Issued Issued per share)
Equity raise 7,479,261 $ 4,634 $ 0.60 $ 0.66
Consultants 15,000 18 1.22 1.22
Conversion of Series A 16,215 - - -
Board and committee members 22,400 15 0.56 0.85
Jackson Investment Group 500,000 324 0.36 0.92
8,032,876 $ 4,991 The Company issued the following shares of
common stock during the Fiscal 2019:
Number of Fair Value Fair Value at Issuance
Common Shares of Shares (minimum and maximum
Shares issued to/for: Issued Issued per share)
Equity raise 3,331,280 $ 5,515 $ 1.40 $ 2.00
Consultants 6,000 10 1.56 1.56
Board and committee members 22,400 32 0.83 1.79
Jackson Investment Group 100,000 75 0.75 0.75
3,459,680 $ 5,632 The Company’s authorized common stock
consists of 40,000,000 shares having a par value of $0.00001. As of the end of Fiscal 2020 and Fiscal 2019, the Company has issued
and outstanding 16,818,624 and 8,785,748 common shares, respectively. In May 2017, the Company entered into an At-The-Market
offering (“ATM”) agreement with Joseph Gunnar & Co., LLC to establish an at-the-market equity offering program
pursuant to which they are able, with the Company’s authorization, to offer and sell up to $3 million of the Company’s
common stock at prevailing market prices from time to time. In Fiscal 2020 and Fiscal 2019, the Company sold 0 and 428,600 shares
of common stock under this program for net proceeds value of $0 and $528 (gross $600), respectively. On January 22, 2019 the Company issued and
sold 387,500 shares of the Company’s common stock to an institutional purchaser at a purchase price of $2.00 per share, for
aggregate gross proceeds of approximately $775, before placement fees and estimated offering expenses. The offering of the Securities
was made under the Company’s shelf registration statement on Form S-3 (Registration No. 333-208910) (the “Registration
Statement”), including a base prospectus, previously filed with and declared effective by the Securities and Exchange Commission
(the “SEC”) on March 22, 2016. The offering of the Securities was made only by means of a prospectus supplement that
forms a part of the registration statement. On February 12, 2019, the Company closed its
previously announced firm commitment underwritten public offering in which, pursuant to an underwriting agreement between the Company
and the underwriter, dated as of February 8, 2019, the Company issued and sold 2,425,000 shares of its common stock, at a public
offering price of $1.65 per share. The gross proceeds from the offering were approximately $4,001 (net $3,078), excluding underwriting
discounts and commissions and other estimated offering expenses. Pursuant to the underwriting agreement, the Company granted the
underwriter an over-allotment option, which is exercisable for up to 45 days following the date of the prospectus for the offering,
to purchase up to 363,750 additional shares of common stock. On March 14, 2019, our underwriters exercised
a portion of the over-allotment option for 90,180 shares at an exercise price of $1.65 per share. The Company received a total
of $138 in net proceeds. On December 23, 2020, the Company entered into
an underwriting agreement with H.C. Wainwright & Co., LLC (“Wainwright”.) Pursuant to the agreement, the Company
agreed to sell 4,188,405 shares of the Company’s common stock to Wainwright at an offering price to the public of $0.60 per
share, less underwriting discounts and commissions. In addition, the Company granted Wainwright a 30-day option to purchase up
to an additional 628,260 shares of common stock at the same offering price to the public, less underwriting discounts and commissions.
On December 28, 2020, Wainwright exercised its option in full to purchase such additional 628,260 shares of common stock. As a
result, the Company issued an aggregate of 4,816,665 shares of common stock under the Underwriting Agreement. On December 30, 2020, the Company entered into
a securities purchase agreement with certain institutional and accredited investors. Pursuant to the agreement, the Company agreed
to sell, in a registered direct offering, 2,662,596 shares of common stock at an offering price of $0.66 per share. February 2021 Public Offering On February 9, 2021, we announced the pricing
of a public offering of an aggregate of 21,855,280 shares of its common stock at a public offering price of $0.90 per share (the
“Offering”.) The Offering was made pursuant to the Company’s registration statement on Form S-1 initially filed
on January 13, 2021, as subsequently amended and declared effective on February 9, 2021. The Offering was made only by means of
a prospectus forming a part of the effective registration statement. The Offering closed on February 12, 2021. In
the Offering, the Company issued 20,851,199 shares of common stock and pre-funded warrants to purchase up to 1,004,081 shares of
common stock, at an exercise price of $0.0001 per share (the “Pre-funded Warrants”.) The Pre-funded Warrants were sold
at $0.8999 per Pre-Funded Warrant. The Pre-funded Warrants were immediately exercisable and could be exercised at any time after
their original issuance until such Pre-funded Warrants were exercised in full. The Pre-funded Warrants were exercised immediately
upon issuance, and 1,004,081 shares of common stock were issued on February 12, 2021. The net proceeds to the Company from the Offering
were approximately $18.1 million, after deducting placement agent fees and estimated offering expenses payable by the Company.
While the Company’s Series E Preferred Stock is outstanding, the Company is required to use the proceeds of any sales of
equity securities, including the securities offered in the Offering, exclusively to redeem any outstanding shares of the Company’s
Series E Preferred Stock, subject to certain limitations. On February 5, 2021, the Company used approximately 75% of the net proceeds
from the Offering to redeem a portion of the outstanding Jackson Note and 25% of the net proceeds from the Offering to redeem a
portion of the Company’s Series E Preferred Stock. Pursuant to the Limited Consent, upon closing of the Offering, the Company
redeemed a portion of the 2020 Jackson Note and redeemed 4,518 shares of the Base Series E Preferred Stock. Following the redemption
of the Base Series E Preferred Stock, the Company has 6,172 shares of Base Series E Preferred Stock outstanding with an aggregate
stated value of $6,172. Restricted Shares The Company has issued shares to employees
and board and committee members under its 2015 Omnibus Incentive Plan and 2016 Omnibus Incentive Plan. Under these plans, the shares
are restricted for a period of three years from issuance. As of Fiscal 2020, the Company has a total of 61,600 shares unvested
issued to employees and Board and committee members. In accordance with ASC 718, Compensation – Stock Compensation, the Company
recognizes stock-based compensation from restricted stock based upon the fair value of the award at issuance over the vesting term
on a straight-line basis. The fair value of the award is calculated by multiplying the number of restricted shares by the Company’s
stock price on the date of issuance. The impact of forfeitures has historically been immaterial to the financial statements. In
Fiscal 2020 and Fiscal 2019, the Company recorded compensation expense associated with these restricted shares of $252 and $539,
respectively. The table below is a rollforward of unvested restricted shares issued to employees and board of directors.
Restricted Shares
Weighted Average Price Per Share
Balance at December 29, 2018 572,256 $ 3.47
Granted 22,400 1.48
Vested/adjustments (4,216 ) 5.52
Balance at December 28, 2019 590,440 $ 3.12
Granted 38,615 0.76
Vested/adjustments (567,455 ) 3.16
Balance at January 2, 2021 61,600 $ 1.25 Series A Preferred Stock – Related
Party On May 29, 2015, the Company filed a Certificate
of Designations, Preferences and Rights of Series A Preferred Stock with the Nevada Secretary of State, whereby the Company designated
1,663,008 shares of preferred stock as Series A Preferred Stock, par value $0.00001 per share. On June 15, 2017, the Company reincorporated
in the State of Delaware. The Series A Preferred Stock has a stated value of $1.00 per share and is entitled to a 12% dividend. Shares of the Series A Preferred Stock are
convertible into shares of common stock at the holder’s election at any time prior to December 31, 2020 (the “Redemption
Date”), at a conversion rate of one and three tenths (1.3) shares of common stock for every 50 shares of Series A Preferred
Stock that the Holder elects to convert. Originally the redemption date was December 31, 2018 and this was extended to December
31, 2020 in January 2019. Except as otherwise required by law, the Series A Preferred Stock shall have no voting rights. In the event of a liquidation, dissolution
or winding up of the Company, the holders of the Series A Preferred Stock shall be entitled to receive out of the assets of the
Company legally available for distribution, prior to and in preference to distributions to the holders of the Company’s common
stock, par value $0.00001 per share or classes and series of securities of the Company which by their terms do not rank senior
to the Series A Preferred Stock, and either in preference to or pari passu with the holders of any other series of Preferred Stock
that may be issued in the future that is expressly made senior or pari passu, as the case may be, an amount equal to the Stated
Value of the Series A Preferred Stock less any dividends previously paid out on the Series A Preferred Stock. The holders will be entitled to receive cash
dividends at the rate of 12% of the Stated Value per annum, payable monthly in cash, prior to and in preference to any declaration
or payment of any dividend on the common stock. So long as any shares of Series A Preferred Stock are outstanding, the Company
shall not declare, pay or set apart for payment any dividend on any shares of common stock, unless at the time of such dividend
the Company shall have paid all accrued and unpaid dividends on the outstanding shares of Series A Preferred Stock. The Certificate of Designation filed on May
29, 2015, designating the Series A Preferred Stock, was filed in connection with the Company’s issuance of an aggregate of
1,663,008 shares of Series A Preferred Stock to Brendan Flood and Matthew Briand for the conversion of the Gross Profit Appreciation
Bonus (as defined in each employment agreement) associated with their employment agreements. The Certificate of Designation was
approved and related issuances were ratified by the Company’s Board and compensation committee on May 29, 2015. Up until the Redemption Date, holders may convert
their shares into common stock at their election. On the Redemption Date, the Company shall redeem all of the shares of Series
A Preferred Stock of each Holder, for cash or for shares of common stock in the Company’s sole discretion. If the Redemption
Purchase Price is paid in shares of common stock, the holders shall initially receive one and three tenths (1.3) shares of common
stock for each $50.00 of the Redemption Purchase Price. If the Redemption Purchase Price is paid in cash, the redemption price
paid to each Holder shall be equal to the Stated Value for each share of Series A Preferred Stock, multiplied by the number of
shares of Series A Preferred Stock held by such Holder, less the aggregate amount of dividends paid to such Holder through the
Redemption Date. On January 21, 2020,
the Company converted the 623,628 Series A Preferred Shares awarded to Mr. Briand into 16,215 shares of common stock. As of Fiscal
2020 and Fiscal 2019, we had issued and outstanding 1,039,380 and 1,663,008 Series A Preferred Stock shares and $125 and $0 accrued
dividends, respectively. In Fiscal 2020 and Fiscal 2019, the Company paid dividends of $0 and $200, respectively. Subsequent to
Fiscal 2020, on January 8, 2021, the remaining 1,039,380 Series A Preferred Shares were converted into 27,024 shares of our common
stock. Series E Preferred Stock The Series E Preferred Stock ranks senior to
common stock and any other series or classes of preferred stock now or after issued or outstanding with respect to dividend rights
and rights on liquidation, winding up and dissolution. Each share of Series E Preferred Stock was initially convertible into 561.8
shares of our common stock at any time after October 31, 2020 or the occurrence of a Preferred Default. A holder of Series E Preferred
Stock is not required to pay any additional consideration in exchange for conversion of such Series E Preferred Stock into our
common stock. Series E Preferred Stock is redeemable by the Company at any time at a price per share equal to the stated value
($1,000 per share) plus all accrued and unpaid dividends thereon. While the Series E Preferred Stock is outstanding, the Company
is required to use the proceeds of any sales of equity securities, exclusively to redeem any outstanding shares of Series E Preferred
Stock, except that the Company is permitted to use up to an aggregate of $3,000 of the gross proceeds from any equity offering
completed on or before November 15, 2019 for working capital purposes. On January 22, 2019, the Company completed a registered
direct offering of our common stock that generated $775 in gross proceeds that are to be used for working capital purposes. On
February 12, 2019, the Company closed its previously announced firm commitment underwritten public offering in which, pursuant
to an underwriting agreement between the Company and the underwriter, dated as of February 8, 2019, the Company issued and sold
2,425,000 shares of its common stock, at a public offering price of $1.65 per share. Notwithstanding the terms of the certificate
of designations for Series E Preferred Stock, Jackson, the holder our outstanding shares of Series E Preferred Stock, did not require
us to use the proceeds from our recent offerings in excess of $3,000 to redeem outstanding shares of the Series E Preferred Stock.
Instead, the Company used such excess proceeds to make a terminal payment to the sellers of first In the event of liquidation, dissolution or
winding up, the holders of the Series E Preferred Stock are entitled to receive out of the Company assets legally available for
distribution, prior to and in preference to distributions to the holders of common stock or classes and series of securities which
by their terms do not rank senior to the Series E Preferred Stock, and either in preference to or pari passu with the holders of
any other series of preferred stock that may be issued in the future that is expressly made senior or pari passu, as the case may
be, an amount equal to the stated value of the Series E Preferred Stock plus any accrued but unpaid dividends. On October 23, 2020, the Company filed the
second amendment to the Certificate of Designation of the Series E Preferred Stock and Series E-1 Preferred Stock. Under the amended
terms, holders of Series E Preferred Stock are entitled to monthly cash dividends on the Company’s Series E Preferred Stock
at a per annum rate of 12%. At the Company’s option, up to 50% of the cash dividend on the Base Series E Preferred Stock
may be paid in kind by adding such 50% portion to the outstanding liquidation value of the Base Series E Preferred Stock, commencing
on October 26, 2020 and ending on October 25, 2021. If the PIK Dividend Payment is elected, a holder of Series E Preferred Stock
is entitled to additional fee to be paid in shares of the Company’s common stock an amount equal to $10 divided by the average
closing price, as reported by Nasdaq of such shares of common stock over the 5 trading days prior to the applicable monthly interest
payment date. If such average market price is less than $0.50, or is otherwise undeterminable because such shares are no longer
publicly traded or the closing price is no longer reported by Nasdaq, then the average closing price for these purposes shall be
deemed to be $0.50, and if such average closing price is greater than $3.50 then the average closing price for these purposes shall
be deemed to be $3.50. Dividends on the Series E-1 Preferred Stock may only be paid in cash. If the Company fails to make dividend
payments on the Series E Preferred Stock, it will be an event of default under the Amended Note Purchase Agreement. Under the terms of the Amendment, shares of
Series E-1 Preferred Stock are convertible into the Company common stock at a conversion rate equal to the liquidation value of
each shares of Series E-1 Preferred Stock divided by $1.00 per share commencing October 31, 2020. Each share of Series E-1 Preferred
Stock has a liquidation value of $1,000 per share. The Company’s shares of Base Series E Preferred Stock are also convertible
into shares of our common stock after October 31, 2022. The conversion rate for our Base Series E Preferred Stock is equal to the
liquidation value of each shares of Base Series E Preferred Stock divided by $1.00 per share. Each share of Base Series E Preferred
Stock has a liquidation value of $1,000 per share. On September 28, 2020, the Company redeemed 1,300 shares of Base Series E Preferred
Stock for $1,300, as such there is currently 11,700 shares of Base Series E Preferred Stock outstanding. As of January 2, 2021, 11,080,000 shares and
1,363,000 shares of common stock were issuable upon the potential conversion of Series E Preferred Stock and Series E-1 Preferred
Stock, respectively. Due to the contingent nature of the cash redemption feature of the Series E-1 Preferred Stock, the Company
classified the shares as mezzanine equity on the consolidated balance sheets. As a result of the February 2021 public offering,
whereby the Company issued 21,855,280 shares of its common stock, the Company no longer has sufficient authorized shares to settle
the Series E and E-1 Preferred stock upon conversion. The Company will recognize the accounting impact of this transaction during
the first quarter of fiscal 2021. Warrants On January 26, 2017, the Company issued the
Warrant to Jackson which entitled Jackson to purchase up to 630,000 shares of common stock at an initial exercise price of $6.75
per share (subject to adjustment.) The Warrant is exercisable beginning on July 25, 2017 for a term of four and a half (4.5) years
thereafter. The exercise price was subject to anti-dilution protection, including protection in circumstances where common stock
is issued pursuant to the terms of certain existing convertible securities, provided that the exercise price shall not be adjusted
below a price that is less than the consolidated closing bid price of the common stock. The Warrant had anti-dilution provisions
which provided the holder with additional warrants and adjusted strike price in the event of stock repurchases by the Company or
additional shares being issued in connection with the Series D Preferred Shares or Lighthouse promissory notes. As such, the Company
has historically classified the Warrant as a liability. On July 17, 2020, the Company issued warrants
to purchase 90,000 shares to a consultant. The warrants have a 5-year term, an exercise price of $1.00 per share and are valued
at $56. In connection with the additional investment
from Jackson, the Company entered into Amendment No. 1 to Amended and Restated Warrant Agreement (“Warrant agreement”)
with Jackson. The Warrant Amendment amended that certain Amended and Restated Warrant Agreement with Jackson, dated as of April
25, 2018 (the “Warrant”), to reduce the exercise price of the Warrant from $5.00 per share to $3.50 per share. The
incremental fair value of repricing the Warrants to $3.50 per share is $135 and was recognized as deferred financing costs to be
amortized over the term of the Jackson Note. On October 26, 2020, in connection with the
entry into the Amended Note Purchase Agreement, the Company entered into Amendment No. 3 to the Amended and Restated Warrant Agreement,
dated April 25, 2018, as amended (the “Warrant”), with Jackson. Pursuant to Amendment No. 3, the exercise price of
the Warrant was reduced from $1.66 per share to $1.00 per share and the term of the Warrant was extended to January 26, 2026. The
modification of the warrants resulting in a fair value adjustment of $126 were recorded as debt discount which will be amortized
over the term of the 2020 Jackson Note using the effective interest method. On December 29, 2020, as partial compensation
for Wainwright’s services as underwriter in the December 23, 2020 underwriting agreement, the Company issued to Wainwright’s
designees warrants to purchase 361,250 shares of common stock. The warrants have a term of five (5) years from the commencement
of sales under the offering, an exercise price of $0.75 per share and are valued at $248. On December 31, 2020, as partial compensation
for Wainwright’s services as placement agent in the December 30, 2020 securities purchase agreement, the Company issued to
Wainwright’s designees warrants to purchase up to 199,695 shares of common stock. The warrants have a term of five (5) years
from the commencement of sales under the offering, an exercise price of $0.82per share and are valued at $127. Transactions involving the Company’s
warrant issuances are summarized as follows:
Weighted
Number of Average
Shares Exercise Price
Outstanding at December 29, 2018 925,934 $ 1.76
Issued — —
Exercised — —
Expired or cancelled — —
Outstanding at December 28, 2019 925,934 $ 1.76
Issued 650,945 0.81
Exercised — —
Expired or cancelled — —
Outstanding at January 2, 2021 1,576,879 $ 0.99 The following table
summarizes warrants outstanding as of January 2, 2021:
Number Weighted Average Weighted
Outstanding Contractual Average
Exercise Price and Exercisable Life (years) Exercise price
$0.75 - $62.50 1,576,879 4.03 $ 0.99
Incentive Plans 2014 Equity Incentive Plan On January 28, 2014, our Board adopted the
2014 Equity Incentive Plan (the “2014 Plan”.) Under the 2014 Plan, we may grant options to employees, directors, senior
management of the Company and, under certain circumstances, consultants. The purpose of the 2014 Plan is to retain the services
of the group of persons eligible to receive option awards, to secure and retain the services of new members of this group and to
provide incentives for such persons to exert maximum efforts for the success of the Company and its affiliates. A maximum of 50,000
shares of common stock has been reserved for issuance under this plan. The 2014 Plan expires on January 28, 2024. As of January
2, 2021, the Company had issued 50,000 options and shares of common stock pursuant to the 2015 Plan and therefore there are no
remaining shares eligible to be issued under the 2014 Plan. 2015 Omnibus Incentive Plan On September 23, 2015, our Board adopted the
2015 Omnibus Incentive Plan (the “2015 Plan”.) This plan has not been approved by our stockholders. Under the 2015
Plan, we may grant a variety of equity instruments to employees, directors, senior management of the Company and, under certain
circumstances, consultants. The purpose of the 2015 Plan is to retain the services of the group of persons eligible to receive
option awards, to secure and retain the services of new members of this group and to provide incentives for such persons to exert
maximum efforts for the success of the Company and its affiliates. The 2015 Plan provides for an aggregate of
90,000 shares of common stock to be available for awards under the 2015 Plan (“Awards”.) The number of shares available
for grant pursuant to Awards under the 2015 Plan is referred to as the “Available Shares.” If an Award is forfeited,
canceled, or if any Option terminates, expires or lapses without being exercised, the common stock subject to such Award will again
be made available for future grant. However, shares that are used to pay the exercise price of an Option or that are withheld to
satisfy the Participant’s tax withholding obligation will not be available for re-grant under the 2015 Plan. The Plan will have a term of ten years and
no further Awards may be granted under the 2015 Plan after that date. As of January 2, 2021, the Company had issued 90,000 in options
and shares of common stock and had 0 unissued securities remaining under this plan. 2016 Omnibus Incentive Plan On October 25, 2016, our Board adopted the
2016 Omnibus Incentive Plan (the “2016 Plan”) to, among other things, attract and retain the best available personnel,
to provide additional incentive to employees, directors and consultants and to promote the success of the Company’s business.
The 2016 Plan’s terms and conditions are similar to that of the 2015 Plan. On January 26, 2017, our stockholders approved
the 2016 Plan, pursuant to which 500,000 shares of the Company’s common stock will be reserved for issuance under stock,
restricted stock and stock option awards. On May 30, 2018, our stockholders approved an amendment to the 2016 Plan to increase
the total number of shares reserved for issuance under the 2016 Plan to 1,250,000 shares of the Company’s common stock. As
of January 2, 2021, we had issued 1,234,276 shares and options to purchase shares of common stock pursuant to the 2016 Plan, leaving
15,724 shares remaining under the 2016 Plan. A summary of option
activity during the Fiscal 2020 and Fiscal 2019 of the Company’s 2014 Equity Incentive Plan, 2015 Omnibus Incentive Plan
and the 2016 Omnibus Incentive Plan is presented below:
Options
Weighted Average Exercise Price
Outstanding at December 29, 2018 111,400 $ 28.46
Granted — —
Exercised — —
Expired or cancelled (34,900 ) 29.99
Outstanding at December 28, 2019 76,500 $ 27.76
Granted — —
Exercised — —
Expired or cancelled — —
Outstanding at January 2, 2021 76,500 $ 27.76 During the Fiscal 2020 and Fiscal 2019, the
Company recorded total share-based payment expense of $27 and $49, respectively, in connection with all options outstanding. The total compensation cost related to options
not yet amortized is $31 at Fiscal 2020. The Company will recognize this charge over approximately 1.5 years. 2016 Long-Term Incentive Plan In May 2016, the Company’s Board approved
the 2016 Long-Term Incentive Plan (the “2016 LTIP”.) This plan was approved by our stockholders on January 26, 2017. The material features of the 2016 LTIP are:
● The maximum number of shares of common stock to be issued under the 2016 LTIP is 260,000 shares;
● The award of performance units is permitted;
● The term of the 2016 LTIP expired on December 31, 2018. Board selected 260,000 shares to adequately
motivate the participants and drive performance for the period. The estimated fair value of the 2016 LTIP plan
based on third party valuation was $136. As of Fiscal 2017, all units had been issued and all compensation expense amortized. For
Fiscal 2019 and Fiscal 2018, the Company recorded $0 and $0 in compensation expense, respectively, associated with the 2016 LTIP.
All the units under this plan expired on December 31, 2018. 2019 Long-Term Incentive Plan In January 2019, the Company’s Board
approved the 2019 Long-Term Incentive Plan (the “2019 LTIP”.) The Board granted 365,000 units to adequately
motivate the participants and drive performance for the period. Units vest upon the following:
● 50% upon the employee being in good standing on December 31, 2020; and,
● 50% upon the average share price of the Company’s common stock during the 90-day period leading up to December 31, 2020, based upon the following Vesting Rate table:
Average 2019 Price Vesting Rate
<$8 per share 0
>$8 per share Pro-rated
>=$12 per share Full Vesting The company has recognized expense of $284
related to the 2019 LTIP in Fiscal 2020. 2020 Omnibus Incentive Plan On June 30, 2020, the Board approved the 2020 Omnibus Incentive
Plan (the “2020 Plan”) pursuant to which we may grant equity incentive awards to key employees, key contractors, and
non-employee directors of the Company. The 2020 Plan provides for the granting of incentive stock options, nonqualified stock options,
stock appreciation rights, restricted stock, restricted stock units, performance awards, dividend equivalent rights, and other
awards, which may be granted singly or in combination, and that may be paid in cash, shares of our common stock, or a combination
of cash and common stock. A total of 750,000 shares of common stock are reserved for grant under the 2020 Plan, plus any awards
reserved under the Company’s prior equity incentive plans, subject to adjustment in certain circumstances to prevent dilution
or enlargement. On September 29, 2020, our stockholders approved the 2020 Plan. As of January 2, 2021, we had issued 31,003 shares
and options to purchase shares of common stock pursuant to the 2020 Plan, therefore leaving 718,997 shares remaining under the
2020 Plan. The 2020 Plan will terminate on June 30, 2030. |
